SARS-CoV-2/COVID-19: Infection Models, Therapeutics and Vaccines, Second Edition
A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Public Health Microbiology".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 68
Special Issue Editor
Interests: antivirals and animals models for emerging viruses including SARS-CoV-2
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is the continuation of our previous Special Issue, entitled “SARS-CoV-2/COVID-19: Infection Models, Therapeutics and Vaccines”.
Almost two years after the emergence of SAR-CoV-2, more than 330 million cases of infection and 5.5 million fatal cases have been reported worldwide. Since the end of 2020, new SARS-CoV-2 variants of concern (VOCs) have been emerging worldwide. These variants present new challenges to the control of the COVID-19 pandemic by greatly threatening the efficacies of available monoclonal antibody therapies and vaccines, which have been developed to target the parent strain of SARS-CoV-2. Therefore, continued efforts are required to evaluate the efficacy of currently available and newly developed therapeutics and vaccines against SARS-CoV-2 (including new variants) in relevant infection models in order to contain and combat this virus efficiently.
Therefore, the aim of this Special Issue is to provide a collection of articles that highlight recent advancements in the battle against the SARS-CoV-2 pandemic. As the Guest Editor of this Special Issue, I invite you to submit research articles, review articles, and short communications related to SARS-CoV-2 infection models and the development of therapeutics and vaccines for use against this virus.
I look forward to receiving your contributions.
Dr. Rana Abdelnabi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- SARS-CoV-2
- animal models
- antivirals
- vaccine
- monoclonal antibodies
- assay models
